Tolerance and Acute Effects of a New HFNT Nasal Cannula

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

December 14, 2022

Study Completion Date

January 31, 2023

Conditions
COPD Exacerbation Acute
Interventions
DEVICE

AIRVO 2, the new asymmetric nasal cannula

The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

All Listed Sponsors
collaborator

Fisher and Paykel Healthcare

INDUSTRY

lead

Temple University

OTHER